BioRestorative Therapies Inc BRTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BRTX is a good fit for your portfolio.
News
-
BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice
-
BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market
-
BioRestorative Therapies Provides First Quarter 2024 Business Update
-
BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity
-
BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
-
BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology
-
BioRestorative Therapies Shares Rise 17% After FDA Clears Phase 2 Study Protocol Amendment
-
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
Trading Information
- Previous Close Price
- $1.29
- Day Range
- $1.22–1.31
- 52-Week Range
- $1.20–7.13
- Bid/Ask
- $1.22 / $1.26
- Market Cap
- $8.67 Mil
- Volume/Avg
- 88,596 / 548,721
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 37.32
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 11
- Website
- https://www.biorestorative.com
Valuation
Metric
|
BRTX
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.53 |
Price/Sales | 37.32 |
Price/Cash Flow | — |
Price/Earnings
BRTX
Financial Strength
Metric
|
BRTX
|
---|---|
Quick Ratio | 10.42 |
Current Ratio | 10.71 |
Interest Coverage | — |
Quick Ratio
BRTX
Profitability
Metric
|
BRTX
|
---|---|
Return on Assets (Normalized) | −47.22% |
Return on Equity (Normalized) | −50.23% |
Return on Invested Capital (Normalized) | −53.41% |
Return on Assets
BRTX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cvhmvpkhj | Gkkt | $593.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bqsqpxz | Hwrjzw | $115.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pyxkqznnh | Cslfcr | $107.2 Bil | |
MRNA
| Moderna Inc | Btjqdtjgw | Wvfq | $58.7 Bil | |
BNTX
| BioNTech SE ADR | Bndcgtjwl | Gwdh | $22.7 Bil | |
ARGX
| argenx SE ADR | Jcntjfd | Ytlqy | $21.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vhgjkntt | Sltqtt | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Cdhlfmn | Zytmkk | $14.1 Bil | |
INCY
| Incyte Corp | Stdkvbb | Dzmgvv | $12.9 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kqwbjvqzh | Jplvf | $12.0 Bil |